A Prospective Randomized Controlled Trial of Dual-Mobility Components in Primary THA

Rush logo

Rush

Status and phase

Active, not recruiting
Phase 4

Conditions

Serum Metal Levels, Specifically Cobalt, Chromium, and Titanium

Treatments

Device: Dual mobility cohort
Device: Conventional cohort

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT03371212
17060804

Details and patient eligibility

About

The aim of this study is to determine if the use of a modular dual mobility bearing is associated with clinically important increases in serum metal levels.

Full description

Prosthetic dislocation following total hip arthroplasty (THA) remains a significant concern with a reported incidence of 0.2%-7.0% after primary and 10%-25% after revision THA. The risk of dislocation following THA is multifactorial and includes both surgeon-related factors (i.e. component positioning, surgical approach) and patient-related factors (i.e. gender, age). Dual mobility articulations have been shown to reduce the incidence of hip instability following THA. Dual mobility implants have been used in Europe for over 30 years, but have recently received an increased interest in the United States. Initial dual mobility designs consisted of a cementless, monoblock acetabular component with a highly-polished metal inner bearing surface. Modular dual mobility prostheses have been introduced in which a modular cobalt-alloy liner is inserted into a hemispherical titanium acetabular component. Advantages of this construct include familiarity of use of a standard titanium acetabular component and the ability to use supplemental screw fixation. However, the potential for fretting corrosion between the cobalt-alloy liner and the titanium acetabular component remains a concern. In a retrospective review of 100 consecutive patients undergoing primary THA using a modular dual mobility prosthesis, the authors found 21% of patients to have a serum cobalt level above the normal range, with 9% significantly above normal (> 1.6 ug/L), at a mean of 27.6 months postoperatively. In addition, a recent prospective cohort study of 26 patients receiving the same prosthesis showed elevated whole blood mean cobalt levels in patients receiving a modular dual mobility prosthesis versus patients receiving a conventional bearing (0.23 + 0.39 vs. 0.15 + 0.07ug/L, p<0.001) at 1 year postoperatively. Four patients in the dual mobility cohort had a whole blood cobalt level outside the reference range (maximum 1.81 ug/L). To the investigators knowledge no prospective, randomized controlled trial has been performed comparing dual mobility bearings to a conventional single-bearing design. Therefore, the purpose of this study is to compare the use of a conventional single-bearing ceramic-on-polyethylene surface to use of a modular dual mobility bearing in a prospective, randomized controlled setting.

Enrollment

52 estimated patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age between 18 and 80 years
  • Willingness to undergo serial postoperative venipuncture for serum meal analysis
  • BMI < 40
  • Patients that are eligible for the requisite implants as deemed by their surgeon

Exclusion criteria

  • Clinically significant systemic chronic disease
  • Diminished renal function
  • Presence of any metal-containing implant outside of the oral cavity
  • History of prior hip surgery involving an internal fixation device
  • History of hip infection
  • Preoperative diagnosis other than osteoarthritis
  • Anticipated need for another joint replacement surgery within one year
  • Patients taking chromium supplements

Trial design

52 participants in 2 patient groups

Conventional Cohort
Active Comparator group
Description:
Patients in this group will receive a Taperloc femoral stem, ceramic femoral head (size 32mm for acetabular components 48/50mm; size 36mm for acetabular components > 52mm), polyethylene bearing, and G7 acetabular shell.
Treatment:
Device: Conventional cohort
Modular Dual Mobility Cohort
Experimental group
Description:
Patients in this group will receive a Taperloc femoral stem, inner ceramic femoral head (28mm), mobile polyethylene bearing, cobalt alloy liner, and G7 acetabular shell.
Treatment:
Device: Dual mobility cohort

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems